Search research articles
Contact Us
Filters
Showing results (71-80 of 109) with videos related to
Page
of 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer
A M E Bos, F Y F L De Vos, E G E de Vries, et al.
Journal of Neurology
|
February 1, 2023
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a
H Vrenken, M Battaglini, M L de Vos, et al.
Clinical Nuclear Medicine
|
May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?
Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Neuro-Oncology Practice
|
July 20, 2022
Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients
Emma van Kessel, Eva A Krijnen, Suzanne IJpelaar, et al.
Gynecologic Oncology
|
March 26, 2005
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma
F Y F L De Vos, A M E Bos, M Schaapveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
J A Gietema, R Hoekstra, F Y F L de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer
Ronald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Targeted Oncology
|
February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
Clinical Nuclear Medicine
|
May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication
Bernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
BMC Cancer
|
September 1, 2022
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study
Naomi C A van der Velden, Hanneke W M van Laarhoven, Sjaak A Burgers, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 109) with videos related to
Sort By:
Page
of 11
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2005
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer
A M E Bos, F Y F L De Vos, E G E de Vries, et al.
Journal of Neurology
|
February 1, 2023
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a
H Vrenken, M Battaglini, M L de Vos, et al.
Clinical Nuclear Medicine
|
May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?
Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Neuro-Oncology Practice
|
July 20, 2022
Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients
Emma van Kessel, Eva A Krijnen, Suzanne IJpelaar, et al.
Gynecologic Oncology
|
March 26, 2005
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma
F Y F L De Vos, A M E Bos, M Schaapveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
J A Gietema, R Hoekstra, F Y F L de Vos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer
Ronald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Targeted Oncology
|
February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
Clinical Nuclear Medicine
|
May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication
Bernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
BMC Cancer
|
September 1, 2022
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study
Naomi C A van der Velden, Hanneke W M van Laarhoven, Sjaak A Burgers, et al.
Page
of 11